Abstract
As an MHC class I protein, the disease association of HLA-B27 with inflammatory arthritis has been widely assumed to imply a role for the T cell antigen receptor (TCR) in disease. However, in addition to their classical antigen-presenting role, HLA class I proteins are recognised by members of the killer immunoglobulin receptor (KIR) and leukocyte immunoglobulin-like receptor (LILR / ILT / LIR) families. Unusual properties of HLA-B27 include an ability of free heavy chains (FHC) to reach the cell surface in the absence of β2m and to maintain their peptide-binding groove in vitro. This review describes immunomodulatory receptors that recognise HLA class I, and the recognition of HLA-B27 in both the classical β2m-associated and β2m-independent forms by members of the KIR and LILR families. Alternative recognition of different forms of HLA-B27 by leukocyte receptors could influence the function of cells from both innate and adaptive immune systems, and may indicate a role for various leukocyte populations in HLA-B27-associated inflammatory disease.
Keywords: hla-b27, spondyloarthropathy, ankylosing spondylitis, heavy chain, hc-b27, tcr
Current Molecular Medicine
Title: Recognition of Classical and Heavy Chain Forms of HLA-B27 by Leukocyte Receptors
Volume: 4 Issue: 1
Author(s): Rachel L. Allen and John Trowsdale
Affiliation:
Keywords: hla-b27, spondyloarthropathy, ankylosing spondylitis, heavy chain, hc-b27, tcr
Abstract: As an MHC class I protein, the disease association of HLA-B27 with inflammatory arthritis has been widely assumed to imply a role for the T cell antigen receptor (TCR) in disease. However, in addition to their classical antigen-presenting role, HLA class I proteins are recognised by members of the killer immunoglobulin receptor (KIR) and leukocyte immunoglobulin-like receptor (LILR / ILT / LIR) families. Unusual properties of HLA-B27 include an ability of free heavy chains (FHC) to reach the cell surface in the absence of β2m and to maintain their peptide-binding groove in vitro. This review describes immunomodulatory receptors that recognise HLA class I, and the recognition of HLA-B27 in both the classical β2m-associated and β2m-independent forms by members of the KIR and LILR families. Alternative recognition of different forms of HLA-B27 by leukocyte receptors could influence the function of cells from both innate and adaptive immune systems, and may indicate a role for various leukocyte populations in HLA-B27-associated inflammatory disease.
Export Options
About this article
Cite this article as:
Allen L. Rachel and Trowsdale John, Recognition of Classical and Heavy Chain Forms of HLA-B27 by Leukocyte Receptors, Current Molecular Medicine 2004; 4 (1) . https://dx.doi.org/10.2174/1566524043479329
DOI https://dx.doi.org/10.2174/1566524043479329 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Pictorial Review of Intracranial Haemorrhage Revisited
Current Medical Imaging Preeclampsia: Placental Origins, New Predictors and New Therapeutic Strategies
Current Women`s Health Reviews New Pharmacological Approaches to the Prevention of Myocardial Ischemia- Reperfusion Injury
Current Drug Targets Kawasakis Disease, Acrodynia, and Mercury
Current Medicinal Chemistry HCV-Related Central and Peripheral Nervous System Demyelinating Disorders
Inflammation & Allergy - Drug Targets (Discontinued) Predictors of Cardiovascular Affection in Patients with Active Rheumatoid Arthritis: Secondary Analysis of a Randomized Controlled Trial
Current Rheumatology Reviews Cannabinoids and Myocardial Ischemia: Novel insights, Updated Mechanisms, and Implications for Myocardial Infarction
Current Medicinal Chemistry Ischemic Colitis: Current Diagnosis and Treatment
Current Drug Targets Predicting Toxicity: Biomarkers and the Value of the Patient's Opinion
Current Pharmaceutical Design Survey of the State of the Art in Biomaterials, Cells, Genes and Proteins Integrated into Micro- and Nanoscaffolds for Tissue Regeneration
Current Nanoscience Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer’s Disease
Current Alzheimer Research Physiological Changes in the Critically Ill Patient with Sepsis
Current Pharmaceutical Biotechnology Modulation of Eosinophil Functions by Nitric Oxide: Cyclic GMPdependent and -independent Mechanisms
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Anesthetic Pharmacology and Perioperative Considerations for Heart Transplantation
Current Clinical Pharmacology Targeted Gene Deletion of Prolyl Hydroxylase Domain Protein 3 Triggers Angiogenesis and Preserves Cardiac Function by Stabilizing Hypoxia Inducible Factor 1 Alpha Following Myocardial Infarction
Current Pharmaceutical Design Resistin and Cardiovascular Disease: A Review of the Current Literature Regarding Clinical and Pathological Relationships
Current Cardiology Reviews Cardiovascular Involvement in Pediatric Systemic Autoimmune Diseases: The Emerging Role of Noninvasive Cardiovascular Imaging
Inflammation & Allergy - Drug Targets (Discontinued) Assessment of Possible Drug Interactions in Patients with Psoriasis and Associated Comorbid Medical Conditions: An Observational Study
Reviews on Recent Clinical Trials Combination of Captopril with Gliclazide Decreases Vascular and Renal Complications and Improves Glycemic Control in Rats with Streptozotocin- Induced Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets The Serpin Solution; Targeting Thrombotic and Thrombolytic Serine Proteases in Inflammation
Cardiovascular & Hematological Disorders-Drug Targets